Typical Dosage Range: 200mcg 500mcg per day
doi:10.1371/journal.pone.0033944 Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ et al (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
2018 data is from a different population (postmenopausal women not on GLP-1 therapy) using a different dose (5g vs
Electrolytes including sodium, potassium, and chloride support nerve conduction, muscle contraction, and cardiovascular function
compared to European markets where Humira biosimilars had quickly gained 50% to 80% market share